Since their discovery in the late 1800s, viruses have been considered simple organisms largely incapable of communication. But today’s virologists have changed their tune; now,
As part of a research partnership aimed at improving the delivery of nucleic acid-based therapies targeting nervous system diseases, American pharmaceutical company Eli Lilly and
Biotech start-up Ring Therapeutics, founded by Flagship Pioneering in 2017, hopes to transform gene therapy by using a new class of vector — anelloviruses –
RNA viruses are known to cause a large number of diseases in humans, including COVID-19, measles, influenza, hepatitis, yellow fever and Zika. Most new and
Since their discovery in the late 1800s, viruses have been considered simple organisms largely incapable of communication. But today’s virologists have changed their tune; now,
As part of a research partnership aimed at improving the delivery of nucleic acid-based therapies targeting nervous system diseases, American pharmaceutical company Eli Lilly and
Biotech start-up Ring Therapeutics, founded by Flagship Pioneering in 2017, hopes to transform gene therapy by using a new class of vector — anelloviruses –
RNA viruses are known to cause a large number of diseases in humans, including COVID-19, measles, influenza, hepatitis, yellow fever and Zika. Most new and
Delaware Technology Park,
3 Innovation Way,
Newark, DE 19711
"*" indicates required fields
Emails are serviced by Constant Contact. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email.
